These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 12973747

  • 21. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
    Nakamura S, Murayama N, Noshita T, Katsuragi R, Ohno T.
    Eur J Pharmacol; 2006 Oct 24; 548(1-3):115-22. PubMed ID: 16952349
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Management of moderate to severe Alzheimer's disease: focus on memantine.
    Dominguez E, Chin TY, Chen CP, Wu TY.
    Taiwan J Obstet Gynecol; 2011 Dec 24; 50(4):415-23. PubMed ID: 22212311
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
    Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG.
    Behav Brain Res; 2011 Aug 10; 221(2):594-603. PubMed ID: 20553766
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA.
    Curr Alzheimer Res; 2005 Apr 10; 2(2):155-65. PubMed ID: 15974913
    [Abstract] [Full Text] [Related]

  • 34. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT, Edwards KR, Zhao Q.
    J Clin Pharmacol; 2006 Jul 10; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [Abstract] [Full Text] [Related]

  • 35. Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease.
    Bordji K, Becerril-Ortega J, Buisson A.
    Rev Neurosci; 2011 Jul 10; 22(3):285-94. PubMed ID: 21568789
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H, Grossberg GT.
    J Clin Pharmacol; 2006 Jul 10; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [Abstract] [Full Text] [Related]

  • 39. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK, Kaul CL, Ramarao P.
    Pharmacol Res; 2005 Jan 10; 51(1):1-17. PubMed ID: 15519530
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.